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Abstract
Background: Antibiotic resistance genes are widely used for selection of recombinant bacteria,
but their use risks contributing to the spread of antibiotic resistance. In particular, the practice is
inappropriate for some intrinsically resistant bacteria and in vaccine production, and costly for
industrial scale production. Non-antibiotic systems are available, but require mutant host strains,
defined media or expensive reagents. An unexplored concept is over-expression of a host essential
gene to enable selection in the presence of a chemical inhibitor of the gene product. To test this
idea in E. coli, we used the growth essential target gene fabI as the plasmid-borne marker and the
biocide triclosan as the selective agent.
Results: The new cloning vector, pFab, enabled selection by triclosan at 1 μM. Interestingly, pFab
out-performed the parent pUC19-ampicillin system in cell growth, plasmid stability and plasmid
yield. Also, pFab was toxic to host cells in a way that was reversed by triclosan. Therefore, pFab
and triclosan are toxic when used alone but in combination they enhance growth and plasmid
production through a gene-inhibitor interaction.
Conclusion: The fabI-triclosan model system provides an alternative plasmid selection method
based on essential gene over-expression, without the use of antibiotic-resistance genes and
conventional antibiotics.
Background
Antibiotic resistance marker genes are commonly used to
select and maintain recombinant bacteria in the presence
of antibiotics. However, the use of antibiotics is undesira-
ble for manufacturing gene therapy products [1,2]. Also,
the introduction of antibiotic resistance genes into bio-
hazardous strains is not recommended [3], and antibiotic
selection fails in bacteria that are naturally resistant [3,4].
Finally, the use of antibiotics can be costly in industrial
scale production, especially in the case of enzymatic
depletion of antibiotic during culture. An alternative sys-
tem should avoid antibiotic resistance markers and thera-
peutic antibiotics, be cost effective, but still be convenient,
robust and flexible.
A variety of strategies for antibiotic-free selection have
been developed, but none are widely used in bacteria. The
first reported non-antibiotic system involves an auxo-
trophic bacterial strain and complementation using a
plasmid-encoded biosynthesis gene, such that only trans-
formants grow on defined media lacking the nutrient [5].
Another system is termed repressor-titration, where the lac
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operator functions as the vector-borne selection marker,
which de-represses a modified chromosomal essential
gene [6]. A third general approach is to alter the expres-
sion of growth essential genes using synthetic [7] or
expressed antisense sequences [8]. Unfortunately, these
and other existing non-antibiotic systems suffer from a
need for mutant host strains or expensive reagents, and in
some cases low efficiency.
It has been observed that over-expression of a growth
essential gene results in reduced susceptibility to the gene
product inhibitor [9]. Here we considered a strategy based
on an essential gene as the plasmid-borne marker and a
specific protein level inhibitor as the selective agent. To
test the idea, we chose fabI-triclosan as a model combina-
tion because it is a well-studied gene-inhibitor pair: FabI
(enoyl ACP reductase) catalyzes fatty acid elongation [10]
and confers reduced susceptibility to triclosan when over-
expressed in E. coli [11,12]; triclosan inhibits FabI through
binding at the ACP-enoyl substrate site, forming a stable
FabI/NAD+/triclosan ternary complex [13]. In addition,
triclosan is a biocide that fulfils the criteria of a non-anti-
biotic [14]. It is stable, easy to handle, inexpensive and
approved for use in many hygiene, household and indus-
trial applications [15,16].
Although triclosan is not used as a systemic therapeutic, it
is important to consider possible risks associated with
new applications. Most importantly, there is concern that
triclosan use may contribute to antibiotic resistance [17];
indeed, resistant mutants can be generated in the labora-
tory [18-20]. However, studies of bacteria in non-labora-
tory conditions exposed to biocide-concentrations of
triclosan did not find a correlation between antibiotic
resistance and decreased triclosan susceptibility [21-23].
Regulatory agencies continue to approve the use of tri-
closan in domestic and clinical products [24,25], and it
appears to be a comparatively safe choice as a selection
agent.
In this study, we tested fabI-marker plasmid selection by
triclosan and observed efficient and stable selection. The
new system out-performed the parent antibiotic system in
growth and plasmid production in the presence of tri-
closan. Cells containing the fabI-marker plasmid dis-
played toxic effects in the absence of triclosan, suggesting
an "addictive" effect, which may aid plasmid contain-
ment.
Methods
Bacterial strains, plasmids and media
The E. coli strains used in this study were DH5α (Invitro-
gen), XL1-Blue (Strategene), HB101, BL21 (Strategene)
and K12 (Coli Genetics Stock Center, Yale U.). Plasmids
were pUC19 (New England Biolabs), pBAD18 and
pBAD18s (National Institute of Genetics, Japan). Media
were SOC and LB (GIBCOBRL) supplemented with amp-
icillin (LBA, 100 μg/ml ampicillin, (Sigma)), triclosan
(LBT, 1 μM triclosan; Ciba) and arabinose (Sigma). Tri-
closan was used as a 1 M stock in DMSO.
Construction of pFab, pUCFA and pBFab
An EagI site was created at nucleotide position 1621 of
pUC19 (New England Biolabs), immediately downstream
of bla, by PCR with primers (5'cgtcggccgttaccaatgcttaatcag
and 5'cgccggccggaccaagtttactcatat). The amplicon was
digested with EagI (New England Biolabs), ligated with T4
DNA ligase and transformed into DH5α for propagation.
To construct pFab, the bla gene was excised from pUC19
with SspI and EagI, and replaced with fabI together with its
promoter, which was amplified from K12 genomic DNA
using the primers 5'ccggatatcgtgctggagaatattcg and
5'gcgcggccgttatttcagttcgagttcgtt. The amplicon was
digested with EcoRV and EagI and used to create the pFab
vector.  E. coli DH5α were transformed with pFab and
plated onto LB with 0.5 – 5 μM triclosan. Transformants
were subsequently maintained in 1 μM triclosan (LBT).
The fabI gene was also cloned into pUC19 at SphI and
BamHI within the MCS (pUCFA) in a similar way using
the primers 5'ccggcatgcgtgctggagaatattcg and 5'ccggatc-
cgattatttcagttcgagt. Competent E. coli DH5α were trans-
formed with pUCFA and plated onto LBA and LBT.
To induce expression of fabI from PBAD, the fabI amplicon
generated from primers (5'cggaattcgaatgggttttctttccgg and
5'cctctagagattatttcagttcgagt) was digested with EcoRI and
XbaI (New England Biolabs) and cloned into pBAD18s,
which was similarly digested, to yield pBFab1. Expression
of fabI in pBAD18 required a Shine Dalgarno sequence,
which was predicted to be uaagga at position -13 relative
to the start codon. Primers (5'cggaattctcaacaataaggat-
taaagc and 5'cctctagagattatttcagttcgagt) were used for
amplification of fabI with its Shine Dalgarno sequence,
and cloned into pBAD18 to yield pBFab6. E. coli DH5α
were transformed with the pBFab plasmids and plated
onto LBA, LBT and LBT with 0.2% (w/v) arabinose.
Plasmid and transformant properties
Transformation efficiencies of chemically competent
DH5α cells were determined as recommended by the
manufacturer (Invitrogen).
Plasmid yields were determined from five clones of
pUC19 and pFab. Plasmids were isolated from one ml
overnight cultures grown under selection using a mini-
prep kit (Qiagen) and quantified by OD260 readings. Plas-
mids (50 ng) were digested with BamHI and
electrophoresed in a 1% agarose gel.BMC Biotechnology 2008, 8:61 http://www.biomedcentral.com/1472-6750/8/61
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Plasmid stability was assayed either in the presence or
absence of selection. Overnight cultures grown under
selection at 37°C with shaking were diluted 1000 × in 5
ml LB with or without selection, and aliquots of the time
zero cultures were diluted and plated onto LB plates con-
taining X-Gal (20 μg/ml, Saveen). The time zero cultures
were grown and diluted as above at 24 and 48 h, and aliq-
uots of the 48 h cultures were plated. The ratios of blue
colonies to total colonies on LB plates with X-Gal (20 μg/
ml) were determined at 0 h and 48 h, from which % plas-
mid-bearing cells at 48 h were calculated. Five independ-
ent clones of pUC19 and pFab were used to provide
replicates.
Plasmid abundance was determined in two ways. First, to
compare band intensities of genomic (gDNA) to plasmid
DNA (pDNA) in an agarose gel, total genomic DNA was
extracted from five different clones of pUC19 and pFab
clones grown under selection for 16 h. Five cultures of
K12, derived from five single colonies, were grown in LB
for DNA extraction using the Bacterial GenElute system
(Sigma) for one ml of overnight culture. Total DNA (10
μl) was electrophoresed in a 1% agarose gel, stained with
ethidium bromide and scanned using a Typhoon 9400
(Amersham Biosciences). Band intensities were deter-
mined by using ImageQuant software (Amersham Bio-
sciences). Second, relative quantitative PCR (qPCR) was
carried out by using the plasmid lacZα gene as the target
gene and single copy chromosomal dxs as the reference
gene [26]. K12 gDNA containing a single copy of lacZα
and dxs was used as a calibrator. Primers amplifying the
target gene (5'gtgctgcaaggcgattaagtt and 5' cactggccgtcgttt-
tacaa), and reference gene (5'cgagaaactggcgatcctta and
5'cttcatcaagcggtttcaca) were validated for similar amplifi-
cation efficiencies. Real time data analyses were carried
out by the 2-ΔΔCT method for relative qPCR [27]. Total
DNA concentrations were determined by OD260 absorb-
ance for qPCR. Each 25 μl of PCR reaction contained 12.5
μl of SYBR Green PCR buffer (Eurogentec), 100 nM of
each primer (Biomers) and 5 ng total DNA.
Growth rates were calculated from the exponential phase
of growth [28], which was monitored as increased OD550
over time by the VERSAmax spectrophotometer (Molecu-
lar Devices). An overnight culture (16 h), standardized by
OD550 to yield approximately 7 × 105 cfu/ml, was grown
in 200 μl volumes per well in a 96-well plate for 24 h with
agitation for 5 s every 5 min, when OD550 readings were
taken. Triclosan was added to give 0 – 2 μM Triclosan and
1% DMSO final concentration.
The host range of pFab within commonly used E. coli
cloning strains was tested by transformation of XL1-Blue
(Stratagene), HB101 and BL21, followed by selection on
LBT plates. Plasmid DNA integrity and abundance was
determined by plasmid extraction, digestion of 100 ng
DNA with BamHI and fractionation in a 1% agarose gel.
Inducible expression of fabI
Clones of pBFab1 and pBFab6 were grown in LBA for 16
h, diluted to approximately 5 – 9 × 106 cfu/ml in LBT and
aliquots of 180 μl were added to wells in a 96 well plate.
Arabinose was added to a final concentration of 0 – 5%
and the final volume per well was made up to 200 μl with
water. Clones of pBAD18 and pBAD18s were included as
controls. Cultures were grown for 24 h in the VERSAmax
spectrophotometer (Molecular Devices) with agitation for
5 s every 5 min, followed by an OD550 reading. The growth
rate at each arabinose concentration was calculated as
described above.
Cell viability
DH5α/pFab were grown overnight in the absence or pres-
ence of 0.5 – 2 μM triclosan and subjected to SYTOX green
staining and flow cytometry, as previously described [29].
DH5α/pUC19 was included as a control to determine
staining levels of live and heat-treated dead cells. Samples
were excited with a 488 nm air-cooled argon ion laser in
the CyFlow SL flow cytometer (Partec GmbH). Threshold
settings were enabled on forward scatter to exclude cell
debris. The forward and side scatter dot plot was used to
identify and gate cell populations. Fluorescence was meas-
ured at 520 nm. Viable and dead cell populations were
counted using the Partec, FloMax software version 2.4e.
Growth competition
Growth competition between DH5α and plasmid bearing
cells was carried out as previously described, with modifi-
cations [30]. Overnight (24 h) cultures of DH5α, DH5α/
pUC19 and DH5α/pFab were prepared in LB, LBA and
LBT, respectively. Equal volumes of DH5α and plasmid
bearing cultures were mixed and diluted 1:100 in 10 ml
fresh LB for further growth. An aliquot of the diluted
mixed culture was simultaneously plated onto selective
and non-selective media for cell counts. After the mixed
culture was incubated for 24 h with shaking at 37°C, it
was diluted 1:100 in 10 ml of fresh LB for further growth
and plated, as above. This procedure was repeated 5 times
over six days. The numbers of ampicillin or triclosan
resistant colonies were scored relative to the total CFUs.
Results
Vectors containing fabI enable triclosan selection
To test the potential of fabI as a selective marker for clon-
ing, two vectors derived from pUC19 were constructed.
First, we constructed pFab, where fabI together with its
native promoter replaces the ampicillin resistance gene
(bla) in pUC19. Second, to enable selection with triclosan
or ampicillin, we constructed pUCFA, which contains the
fabI cassette cloned into the pUC19 MCS (Figure 1A). E.BMC Biotechnology 2008, 8:61 http://www.biomedcentral.com/1472-6750/8/61
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coli strain DH5α was transformed with pFab, pUCFA or
pUC19 and transformants were selected on LB plates con-
taining triclosan (LBT) or ampicillin (LBA). As antici-
pated,  fabI  inserts enabled selection on triclosan
containing plates. Colonies formed on LBT were more
variable in size than colonies on LBA. However, triclosan-
resistant colonies of all sizes maintained resistance (Figure
1B) and displayed uniform colony morphologies upon re-
plating. In contrast to pUC19, we did not observe plas-
mid-free colonies or satellite colonies when using pFab
and pUCFA. Therefore, the fabI-triclosan system enables
non-antibiotic selection and maintains stable recom-
binant strains.
To test whether fabI-triclosan selection could function
well in other E. coli strains, pFab was transformed into
strains BL21, HB101 and XL1-blue. Similar to the results
in DH5α, we observed efficient selection and high yield
plasmid production (Figure 1C). To test whether fabI can
enable triclosan selection in other vectors, the pFab cas-
sette was inserted into the multiple cloning site of pGEM-
3Zf and also used to replace the ampicillin resistance gene
in the low copy number vector pBR322. In both cases, tri-
closan resistant colonies were selected (data not shown).
Therefore, the fabI-triclosan system enables efficient selec-
tion in commonly used vectors and E. coli strains.
To confirm that fabI expression was the main mechanism
mediating triclosan resistance and not point mutations
within chromosomal fabI  [12], expression of fabI  was
placed under the control of the PBAD  promoter in
pBAD18s (pBFab1) and pBAD18 (pBFab6) [31]. The
pBFab1 and pBFab6 strains were tested for resistance fol-
lowing fabI induction. In the absence of the inducer arab-
inose, no growth was observed in LBT broth, but growth
rates increased with increasing arabinose concentrations
up to 0.4% (Figure 2). Therefore, pFab-mediated resist-
ance to triclosan is due to expression of fabI.
Figure 1
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Vector construction and triclosan selection Figure 1
Vector construction and triclosan selection. (A) The 
bla gene in pUC19, which confers ampicillin resistance, was 
replaced with fabI and its promoter region (pFab). The 
pUC19 multiple cloning site (MCS) is retained, however Hin-
cII, HindIII and PstI are not unique in pFab. The fabI cassette in 
pFab can be transferred to other pUC-derived plasmids using 
the AatII and AlwNI restriction sites. The fabI cassette was 
also inserted into the MCS of pUC19 to obtain pUCFA. All 
plasmids are available from the authors. (B) Growth of pFab 
and pUCFA clones on LBT and LBA plates. (C) Plasmids 
propagated in different E. coli hosts were digested with 
BamHI and analyzed by gel electrophoresis.BMC Biotechnology 2008, 8:61 http://www.biomedcentral.com/1472-6750/8/61
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Characterization of pFab
After selection of pFab transformants with triclosan, we
characterized the general properties of pFab as a cloning
vector, with pUC19 included for comparison (Table 1).
Plasmid preparation yield of pFab was 43% greater than
pUC19 (Table 1) in E. coli DH5α transformants. Also, the
copy number of pFab was 38% and 40% greater than that
of pUC19, as measured by qPCR and plasmid to genomic
DNA abundance (Table 1; Figure 3A & B), respectively.
Therefore, pFab displayed higher yield and copy number
relative to the parent vector.
To assess plasmid stability, we first scored the number of
triclosan resistant colony forming units relative to total
colony forming units. Surprisingly, we observed more col-
onies on LBT than on LB plates. This indicated high plas-
mid stability in the presence of triclosan, but some form
of pFab-mediated toxicity in the absence of triclosan.
Indeed, measurements of plasmid stability using an alter-
native α-complementation assay revealed that pFab was
more stable than pUC19 under selection (Table 1). There-
fore, while pFab over-expression clearly conferred tri-
closan resistance, it also appeared to confer a requirement
for the biocide.
Effects of pFab and triclosan on E. coli growth, survival 
and fitness
To further investigate the interaction between fabI and tri-
closan, we first examined culture growth profiles. While
ampicillin had little effect on DH5α/pUC19 cultures, the
final optical density of DH5α/pFab was highest in the
presence of triclosan and the exponential phase growth
rates of DH5α/pFab cultures were faster than DH5α/
pUC19 cultures under selection, whereas the inverse was
observed without selection (Figure 4A; Table 1). We next
determined DH5α/pFab culture growth rates in the pres-
ence of a range of triclosan concentrations (0 – 2 μM). As
pFab was unstable without triclosan, DH5α/pUCFA
grown in LBA was included to prevent the growth of com-
peting plasmid-free cells. Growth rates of pUCFA and
pFab clones were lowest without triclosan and increased
with triclosan addition up to 1 μM, indicating a triclosan-
dependent fitness rescue in cells that carry pFab (Figure
4B). Similarly, we observed that the proportion of dead
cells decreased with increasing triclosan concentrations.
Fluorescence microscopy of the SYTOX stained cells [29]
revealed elongated and dead cells in the absence of tri-
closan, and elongated and viable cells in 1 μM triclosan
(data not shown). The ratio of live to dead cells indicated
by SYTOX staining was then quantified by flow cytometry
[29]. The results again showed that triclosan reduced the
number of dead cells, indicating that pFab transformants
were rescued by triclosan (Figure 4C). Therefore, pFab is
toxic but this toxicity is suppressed by triclosan.
Effect of fabI induction on triclosan resistance Figure 2
Effect of fabI induction on triclosan resistance. Tri-
closan resistance mediated by arabinose-induced over-
expression of fabI. Exponential growth rates are for DH5α/
pBFab1 and DH5α/pBFab6 relative to DH5α/pBAD18s and 
DH5α/pBAD18, respectively.
Plasmid production of pFab transformants Figure 3
Plasmid production of pFab transformants. (A) Agar-
ose gel electrophoresis of total DNA isolated from five 
clones of pUC19 and pFab. Bands were quantified by using 
ImageQuant software to calculate ratio of pDNA to gDNA 
as a measure of copy number in pUC19 and pFab. (B) Mean 
ratios of pDNA:gDNA of pUC19 and pFab from (A).
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To test whether triclosan resistance is likely to persist out-
side intended applications, we assessed the fitness of
DH5/pUC19 and DH5/pFab strains in mixed culture with
the plasmid-free parent strain. A competitive fitness assay,
conducted in the absence of selection, showed that pFab
persistence was weaker than that of pUC19 during co-cul-
ture over six days (Figure 4D). In other words, the rate of
pFab loss was faster than pUC19 loss and therefore, in the
absence of selection, pFab is less stable and less competi-
tive than pUC19.
Discussion
We describe over-expression of a growth essential gene
conferring resistance to a specific protein inhibitor as a
plasmid selection system in E. coli, using fabI and triclosan
as an example. As well as avoiding the use of antibiotic
resistance genes and antibiotics, pFab transformants
showed improved growth, yield and gene containment.
These improvements appear to be due to the mechanism
of inhibition [13] and a balance of toxic gene-inhibitor
levels required for cell survival [32] and selection [33].
Similar interactions in other systems suggest that gene-
inhibitor reciprocal suppression may be a common mech-
anism. For example, reciprocal or mutual suppression has
been described between two genes [34] and chemical
inhibitors [35]. Also, antibiotic-dependent strains have
been described for bacteria isolated from laboratories
[36,37] and clinics [38].
The new selection system relies on an endogenous E. coli
gene and a widely used biocide. Nevertheless, the relative
safety of triclosan and fabI in this application should be
considered. Triclosan is approved by regulatory authori-
ties in the EU and the USA for many applications [24,25]
and an association between bacterial triclosan resistance
and antibiotic susceptibility, though suggested, has not
been found in practice [21-23,39,40]. In the laboratory,
spontaneous triclosan resistance in E. coli resulting from
exposure to low triclosan concentration has been
observed, where three point mutations in fabI increased
MIC by up to 95 fold [12]. Such mutations may arise dur-
ing triclosan selection. However, in our experiments, tri-
closan resistance was dependent on expression of
plasmid-borne fabI (Figure 2), and blue-white selection of
recombinant E. coli indicated mostly pFab-carrying cells
(blue) and very few spontaneous resistant mutants (Table
1). In the environment, triclosan resistance has been slow
to emerge compared to antibiotic resistance [21,23], pos-
sibly due to poor solubility of triclosan [41], rapid degra-
dation of triclosan [22,42,43], low competitive fitness of
FabI mutants [12], and the tripartite nature of the FabI/
NADPH/triclosan complex. Furthermore, the spread of
pFab outside of intended applications should be limited
due to low plasmid stability, poor competitive fitness and
cell toxicity in the absence of triclosan. Indeed, FabI is
stringently regulated within the fatty acid biosynthesis
pathway [32], and de-regulation inhibits cell growth and
viability [44,45]. Nevertheless, it is possible that pFab
could transfer horizontally and thus induce resistance to
triclosan in wild-type bacteria, and standard precautions
in the handling of genetically modified microorganisms
should be maintained.
In large scale production of proteins, plasmid stability
without selection is a pre-requisite because residual anti-
biotics are undesirable. In this regard, the finding that
pFab requires triclosan for plasmid stability could be a
disadvantage. However, the amount of triclosan required
is much less compared to that in antibiotic selection (typ-
ically 2%), and a level of residual triclosan may be permis-
sible, given its approval for use in non-prescription
medicines and hygiene products. Therefore, the need for
Table 1: Properties of pFab and pUC19
Parametersa pUC19 pFab
Transformation efficiencyb (CFU/μg) 5.5 × 107 ± 1.2 × 107 2.2 × 107 ± 3.6 × 106
Plasmid yieldc (μg/ml) 30 ± 2.1 42.9 ± 3.5
Copy numberd 141 ± 25 200 ± 33
Stability (%)
With selectione 85.3 ± 10.8 99.5 ± 1.5
Without selectionf 56.7 ± 17.7 54.5 ± 14.9
Relative growth rateg (ΔOD/Δt)
With selection 1 1.2 ± 0.07
Without selection 1.1 ± 0.05 0.6 ± 0.02
a Determined from five replicate cultures.
b In chemically competent DH5α cells.
c Plasmid yield from 1 ml of 18 h culture, determined by OD260 absorbance.
d Determined from the copy ratio of lacZα to dxs by qPCR.
e Percentage of plasmid-bearing cells at 48 h in cultures grown with selection.
f Percentage of plasmid-bearing cells at 48 h in cultures grown without selection.
g Change in OD550 over time of DH5α/pUC19 cultures in LB and DH5α/pFab in LB or LBT, relative to control DH5α/pUC19 cultures in LBA.BMC Biotechnology 2008, 8:61 http://www.biomedcentral.com/1472-6750/8/61
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stability in the absence of selection may prove less impor-
tant with this system. Nevertheless, pFab stability is a
potential problem and vector construct or process adjust-
ments may be needed during scale-up.
Conclusion
In summary, this study provides an example of how essen-
tial genes can be used in combination with non-antibiotic
inhibitors to select and maintain recombinant bacteria. It
may be possible to apply triclosan selection to other bac-
teria such as Staphylococcus aureus [46] and Mycobacterium
smegmatis [47], which have homologues of FabI. Other
inhibitors of FabI have been described [48,49] and,
depending on bacterial resistance development, certain
triclosan analogues may be preferred for use in this plas-
mid selection system. On the other hand, bacteria that
have divergent enoyl-ACP reductase, such as Bacillus subti-
lis (FabL) [50] and Streptococcus pneumoniae (FabK) [51],
and species that are intrinsically resistant to triclosan,
such as Pseudomonas aeruginosa [18], are not suitable for
fabI-triclosan plasmid selection. For such species, it would
be interesting to test additional essential gene inhibitor
combinations to expand the plasmid selection strategy
described here. The pFab and triclosan system is poten-
tially attractive for production of recombinant proteins,
because it can be used to increase plasmid copy number
and yield. In addition, pFab and its derivatives may be
suitable for manufacturing biopharmaceuticals and gene
therapy products, and in other applications that require
an absence of antibiotic resistance sequences or antibiotic
residues.
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against time represents the rate of plasmid loss in mixed cell 
populations. The data is representative of two independent 
experiments.BMC Biotechnology 2008, 8:61 http://www.biomedcentral.com/1472-6750/8/61
Page 8 of 9
(page number not for citation purposes)
ried out flow cytometry and FACS analysis, and helped
with design and drafting the manuscript. All authors have
read and approved the final manuscript.
Acknowledgements
We thank the Swedish Institute for a Guest Scholarship for SG and the 
Swedish Research Council and University of London Central Research 
Fund for support. We also thank Thomas Bentin, Omid Faridani, Abbas 
Nikravesh, Mónica Marta, Joshua Fink and Rikard Dryselius for help and 
comments.
References
1. Points to consider in the production and testing of new drugs
and biologicals produced by recombinant DNA technology
[http://www.fda.gov/cber/gdlns/ptcdna.htm]
2. Validation of growth-based rapid microbiological methods
for sterility testing of cellular and gene therapy products
[http://www.fda.gov/cber/gdlns/stercgtp.htm]
3. Titball RW, Sjostedt A, Pavelka MS Jr, Nano FE: Biosafety and
selectable markers.  Ann N Y Acad Sci 2007, 1105:405-417.
4. Fajardo A, Martinez-Martin N, Mercadillo M, Galan JC, Ghysels B,
Matthijs S, Cornelis P, Wiehlmann L, Tummler B, Baquero F, Martinez
JL: The neglected intrinsic resistome of bacterial pathogens.
PLoS ONE 2008, 3:e1619.
5. Gonzalez A, Davila G, Calva E: Cloning of a DNA sequence that
complements glutamine auxotrophy in Saccharomyces cere-
visiae.  Gene 1985, 36:123-129.
6. Cranenburgh RM, Hanak JA, Williams SG, Sherratt DJ: Escherichia
coli strains that allow antibiotic-free plasmid selection and
maintenance by repressor titration.  Nucleic Acids Res 2001,
29:E26.
7. Dryselius R, Nekhotiaeva N, Nielsen PE, Good L: Antibiotic-free
bacterial strain selection using antisense peptide nucleic
acid.  Biotechniques 2003, 35:1060-1064.
8. Mairhofer J, Pfaffenzeller I, Merz D, Grabherr R: A novel antibiotic
free plasmid selection system: advances in safe and efficient
DNA therapy.  Biotechnol J 2008, 3:83-89.
9. Xu HH, Real L, Bailey MW: An array of Escherichia coli clones
over-expressing essential proteins: a new strategy of identi-
fying cellular targets of potent antibacterial compounds.  Bio-
chem Biophys Res Commun 2006, 349:1250-1257.
10. Bergler H, Wallner P, Ebeling A, Leitinger B, Fuchsbichler S, Aschauer
H, Kollenz G, Hogenauer G, Turnowsky F: Protein EnvM is the
NADH-dependent enoyl-ACP reductase (FabI) of
Escherichia coli.  J Biol Chem 1994, 269:5493-5496.
11. Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO: Broad spectrum
antimicrobial biocides target the FabI component of fatty
acid synthesis.  J Biol Chem 1998, 273:30316-30320.
12. McMurry LM, Oethinger M, Levy SB: Triclosan targets lipid syn-
thesis.  Nature 1998, 394:531-532.
13. Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO: Mech-
anism of triclosan inhibition of bacterial fatty acid synthesis.
J Biol Chem 1999, 274:11110-11114.
14. Russell AD: Biocide use and antibiotic resistance: the rele-
vance of laboratory findings to clinical and environmental
situations.  Lancet Infect Dis 2003, 3:794-803.
15. Panagakos FS, Volpe AR, Petrone ME, DeVizio W, Davies RM, Proskin
HM: Advanced oral antibacterial/anti-inflammatory technol-
ogy: A comprehensive review of the clinical benefits of a tri-
closan/copolymer/fluoride dentifrice.  J Clin Dent 2005,
16(Suppl):S1-19.
16. Wohlrab J, Jost G, Abeck D: Antiseptic efficacy of a low-dosed
topical triclosan/chlorhexidine combination therapy in
atopic dermatitis.  Skin Pharmacol Physiol 2007, 20:71-76.
17. Aiello AE, Larson E: Antibacterial cleaning and hygiene prod-
ucts as an emerging risk factor for antibiotic resistance in the
community.  Lancet Infect Dis 2003, 3:501-506.
18. Chuanchuen R, Beinlich K, Hoang TT, Becher A, Karkhoff-Schweizer
RR, Schweizer HP: Cross-resistance between triclosan and
antibiotics in Pseudomonas aeruginosa is mediated by multid-
rug efflux pumps: exposure of a susceptible mutant strain to
triclosan selects nfxB mutants overexpressing MexCD-OprJ.
Antimicrob Agents Chemother 2001, 45:428-432.
19. Braoudaki M, Hilton AC: Adaptive resistance to biocides in Sal-
monella enterica and Escherichia coli O157 and cross-resist-
ance to antimicrobial agents.  J Clin Microbiol 2004, 42:73-78.
20. Karatzas KA, Webber MA, Jorgensen F, Woodward MJ, Piddock LJ,
Humphrey TJ: Prolonged treatment of Salmonella enterica
serovar Typhimurium with commercial disinfectants selects
for multiple antibiotic resistance, increased efflux and
reduced invasiveness.  J Antimicrob Chemother 2007, 60:947-955.
21. Cole EC, Addison RM, Rubino JR, Leese KE, Dulaney PD, Newell MS,
Wilkins J, Gaber DJ, Wineinger T, Criger DA: Investigation of anti-
biotic and antibacterial agent cross-resistance in target bac-
teria from homes of antibacterial product users and
nonusers.  J Appl Microbiol 2003, 95:664-676.
22. McBain AJ, Bartolo RG, Catrenich CE, Charbonneau D, Ledder RG,
Price BB, Gilbert P: Exposure of sink drain microcosms to tri-
closan: population dynamics and antimicrobial susceptibility.
Appl Environ Microbiol 2003, 69:5433-5442.
23. Beier RC, Duke SE, Ziprin RL, Harvey RB, Hume ME, Poole TL, Scott
HM, Highfield LD, Alali WQ, Andrews K, et al.: Antibiotic and Dis-
infectant Susceptibility Profiles of Vancomycin-Resistant
Enterococcus faecium (VRE) Isolated from Community
Wastewater in Texas.  Bull Environ Contam Toxicol 2008.
24. Opinion on triclosan resistance   [http://www.europa.eu.int/
comm/food/fs/sc/ssc/out269_en.pdf]
25. Drug approvals   [http://www.fda.gov/cder/da/da1201.htm]
26. Lee C, Kim J, Shin SG, Hwang S: Absolute and relative QPCR
quantification of plasmid copy number in Escherichia coli.  J
Biotechnol 2006, 123:273-280.
27. Livak KJ, Schmittgen TD: Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) Method.  Methods 2001, 25:402-408.
28. Nilsson AI, Zorzet A, Kanth A, Dahlstrom S, Berg OG, Andersson DI:
Reducing the fitness cost of antibiotic resistance by amplifi-
cation of initiator tRNA genes.  Proc Natl Acad Sci USA 2006,
103:6976-6981.
29. Roth BL, Poot M, Yue ST, Millard PJ: Bacterial viability and anti-
biotic susceptibility testing with SYTOX green nucleic acid
stain.  Appl Environ Microbiol 1997, 63:2421-2431.
30. Lenski RE, Simpson SC, Nguyen TT: Genetic analysis of a plas-
mid-encoded, host genotype-specific enhancement of bacte-
rial fitness.  J Bacteriol 1994, 176:3140-3147.
31. Guzman LM, Belin D, Carson MJ, Beckwith J: Tight regulation,
modulation, and high-level expression by vectors containing
the arabinose PBAD promoter.  J Bacteriol 1995, 177:4121-4130.
32. Heath RJ, Rock CO: Regulation of fatty acid elongation and ini-
tiation by acyl-acyl carrier protein in Escherichia coli.  J Biol
Chem 1996, 271:1833-1836.
33. Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton
E, Nichols WW, Colls JG, Minshull CA, Jude DA, et al.: Kinetic and
structural characteristics of the inhibition of enoyl (acyl car-
rier protein) reductase by triclosan.  Biochemistry 1999,
38:12514-12525.
34. Weitao T, Nordstrom K, Dasgupta S: Mutual suppression of
mukB and seqA phenotypes might arise from their opposing
influences on the Escherichia coli nucleoid structure.  Mol
Microbiol 1999, 34:157-168.
35. Yue TF, Dayton PG, Gutman AB: Mutual Suppression of the Uri-
cosuric Effects of Sulfinpyrazone and Salicylate: a Study in
Interactions between Drugs.  J Clin Invest 1963, 42:1330-1339.
36. Wild DG: Reversion from erythromycin dependence in
Escherichia coli: strains altered in ribosomal sub-unit associa-
tion and ribosome assembly.  J Gen Microbiol 1988,
134:1251-1263.
37. Goldstein F, Perutka J, Cuirolo A, Plata K, Faccone D, Morris J, Sour-
nia A, Kitzis MD, Ly A, Archer G, Rosato AE: Identification and
phenotypic characterization of a beta-lactam-dependent,
methicillin-resistant Staphylococcus aureus strain.  Antimicrob
Agents Chemother 2007, 51:2514-2522.
38. Van Bambeke F, Chauvel M, Reynolds PE, Fraimow HS, Courvalin P:
Vancomycin-dependent Enterococcus faecalis clinical isolates
and revertant mutants.  Antimicrob Agents Chemother 1999,
43:41-47.
39. Aiello AE, Marshall B, Levy SB, Della-Latta P, Larson E: Relationship
between triclosan and susceptibilities of bacteria isolated
from hands in the community.  Antimicrob Agents Chemother 2004,
48:2973-2979.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biotechnology 2008, 8:61 http://www.biomedcentral.com/1472-6750/8/61
Page 9 of 9
(page number not for citation purposes)
40. Gilbert P, McBain A, Sreenivasan P: Common therapeutic
approaches for the control of oral biofilms: microbiological
safety and efficacy.  Clin Microbiol Infect 2007, 13(Suppl 4):17-24.
41. Orvos DR, Versteeg DJ, Inauen J, Capdevielle M, Rothenstein A, Cun-
ningham V: Aquatic toxicity of triclosan.  Environ Toxicol Chem
2002, 21:1338-1349.
42. Federle TW, Kaiser SK, Nuck BA: Fate and effects of triclosan in
activated sludge.  Environ Toxicol Chem 2002, 21:1330-1337.
43. Aranami K, Readman JW: Photolytic degradation of triclosan in
freshwater and seawater.  Chemosphere 2007, 66:1052-1056.
44. Keating DH, Carey MR, Cronan JE Jr: The unmodified (apo) form
of Escherichia coli acyl carrier protein is a potent inhibitor of
cell growth.  J Biol Chem 1995, 270:22229-22235.
45. Subrahmanyam S, Cronan JE Jr: Overproduction of a functional
fatty acid biosynthetic enzyme blocks fatty acid synthesis in
Escherichia coli.  J Bacteriol 1998, 180:4596-4602.
46. Heath RJ, Li J, Roland GE, Rock CO: Inhibition of the Staphyloco-
ccus aureus NADPH-dependent enoyl-acyl carrier protein
reductase by triclosan and hexachlorophene.  J Biol Chem 2000,
275:4654-4659.
47. McMurry LM, McDermott PF, Levy SB: Genetic evidence that
InhA of Mycobacterium smegmatis is a target for triclosan.
Antimicrob Agents Chemother 1999, 43:711-713.
48. Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, Jawor-
ski DD, McManus E, Miller WH, Moore TD, Payne DJ, et al.: 1,4-Dis-
ubstituted imidazoles are potential antibacterial agents
functioning as inhibitors of enoyl acyl carrier protein reduct-
ase (FabI).  Bioorg Med Chem Lett 2001, 11:2061-2065.
49. Lu H, Tonge PJ: Inhibitors of FabI, an Enzyme Drug Target in
the Bacterial Fatty Acid Biosynthesis Pathway.  Acc Chem Res
2008, 41:11-20.
50. Heath RJ, Rock CO: A triclosan-resistant bacterial enzyme.
Nature 2000, 406:145-146.
51. Marrakchi H, Dewolf WE Jr, Quinn C, West J, Polizzi BJ, So CY, Hol-
mes DJ, Reed SL, Heath RJ, Payne DJ, et al.: Characterization of
Streptococcus pneumoniae enoyl-(acyl-carrier protein)
reductase (FabK).  Biochem J 2003, 370:1055-1062.